The "Pharmaceutical Speed Reader" market was advised to withdraw the bankruptcy and reorganization of the controlling shareholders of Yuheng Pharmaceuticals.

single city drug collection was "advised to withdraw"; Xu Xinhua, president of Zhongzhu Medical, resigned; Yu Heng Pharmaceuticals' controlling shareholder filed for bankruptcy reorganization; and NMPA released three heavyweight documents, such as "Breakthrough Therapeutic Drug Review Procedure"The State Drug Administration has issued three heavyweight documents, the Procedures for the Review of Breakthrough Therapeutic Drugs (Trial) and the Review and Approval Procedures for The Application for Approval of Drug Conditional Approvals (Trial) and the Priority Review and Approval Procedures for Drug Listing Permits (Trial)Effective from the date of publicationThe "Opinion on The Priority Review and Approval of Encouraging Drug Innovation" issued by the former General Administration of Food and Drug Administration in December 2017 (No126 of THE Food and Drug Administration (2017) ) shall be repealed at the same time(State Drug Administration)7, Hebei Province Medical Insurance Bureau issued "on the further strengthening of centralized procurement management and related issues of the notice", hoping to be scientific, institutionalized, fine management, regulate the centralized procurement behavior, listed the relevant requirements for overall planningFor example, local collection and collection need to be approved by the provincial health insurance bureau(Hebei Health Insurance Bureau)8, Zhongzhu Medical issued a notice that the board of directors recently received the company's president, MrXu Xinhua submitted the resignation reportMrXu Xinhua applied to the board of directors of the company for personal reasons to resign as president of the company(Sina Pharmaceutical News)Yuheng Pharmaceuticals issued a notice that Yuheng Group creditors, on the grounds that Yuheng Group is unable to pay off the debts due and assets are not sufficient to pay off all the debts, filed for bankruptcy reorganization of Yuheng Group from the Harbin Intermediate People's Court in Heilongjiang ProvinceThe Harbin Intermediate People's Court of Heilongjiang Province accepted the case and ruled as follows: Acceptthement of the bankruptcy reorganization application of Yu Heng Group's creditors against Yu Heng Group7, Heppell announced the results of the issuance of overseas listed foreign shares (H shares), said it would sell about 220 million H-shares worldwide, of which 880.38 million shares were issued in Hong Kong, about 132 million shares were sold internationally, and the net proceeds from the global offering were estimated at HK$3,805.7 millionIt will be listed on the Main Board of the Stock Exchange tomorrow(Pharma Rubik's Cube)Haizheng Pharmaceuticals announced that the company is planning a restructuring, through the issuance of shares, convertible corporate bonds and cash payments to HPPC Holding SARL to buy a 49% stake in Hanyu Pharmaceutical Co., Ltd., and to raise supporting fundsThis transaction constitutes an associated transaction and is expected to constitute a material asset reorganization and does not constitute a reorganization listing, the biotech company dragonfly Therapeutics, which develops NK cell therapy, has announced a new research partnership with pharmaceutical giant BMS to develop new immunotherapy for multiple sclerosis and neuro-inflammatory-related targets using Dragonfly's proprietary technology(Pharmaceutical Rubik's Cube)on the 8th, the State Drug Administration issued a notice that, in accordance with the provisions of the "Prescription and Over-the-Counterdrug Classification Management Measures (Trial)" (State Drug Administration Order No10), after organizational demonstration and validation, dredging particles and other 17 drugs from prescription drugs into over-the-counter drugs; (National Drug Administration)ViiV Healthcare announced on July 7, based on the HIV Prevention Trial Network (HPTN) 083 study analysis data, compared with the daily oral enquatertin / tenofofufuma acid tablets (FTC /TDF, 200mg/300mg, Truvada) every two months, the drug is more effective(Sina Pharmaceutical News)Beida Pharmaceuticals Class 1 new drug MRX2843 tablets start phase 1 clinical, intended for late-stage solid tumorMRX2843 is a new, powerful, oral bioavailable small molecule inhibitor and a new chemical structure owned by Beida, MerTyinine Kinase (MerTK) and FMS-like tyrosine kinase 3 (FLT3) double inhibitor(Insight Database)Amyo Shoho announced that the IM19 clinical trial for relapsing/difficult treatment of non-Hodgkin's lymphoma has passed the Beijing Cancer Hospital Ethics Review and will soon launch Phase I clinical trialsThe purpose of the experiment is to assess the safety and initial effectiveness of IM19(Pharma Rubik's Cube) Yahong Pharmaceuticals today announced that its international multi-center phase III clinical study of APL-1702 (Cevira ®) for non-surgical treatment of pre-cervical cancer lesions has been approved by the State Drug Administration and issued a "Notice of Approval of Drug Clinical Trials." (Ameri) Fuhong Hanxuan "Qutozhu monobifying biosimilar drug" in the domestic market review has left the CDE review queue, after completing two rounds of supplementary information, production site inspection, clinical trial on-site verification, is expected to be approved for listing in the near future, becoming the first domestic qutodzumab biosimilar drug (Insight Database) recently, the application for listing of a new class 1 drug, benzosulfoate, developed by HumanFu Pharmaceuticals (acceptance number: CXHS1800035) is expected to be approved for listing in the near future after completing two rounds of supplementary information, on-site inspection of production sites and on-site verification of clinical trials (CPhI Pharmaceutical Online) 8, China's State Drug Administration Drug Review Center recently announced that Roche submitted the IL-6 monoclonal antibody tocilzumab new indication application This is the third time since 2010 and 2016 that Tozhu Sing anti-Singhas has submitted a listing application in China Novartis TIM-3 mono-anti-MBG453 was approved for clinical treatment in China, in conjunction with aphasiad systrentos in the treatment of patients with IPSS-R stratification risk, high-risk or extremely high-risk myelogencytic abnormal syndrome (MDS) or chronic granulocytic leukemia-2 (CMML-2) July 7 local time, Novartis announced that the European Commission has approved Enerzair Breezhaler as a maintenance therapy for adults with asthma who receive long-acting beta 2 receptor agonists and high-dose inhaled corticosteroid combination synodals that do not adequately control the condition and have experienced one or more acute asthma exacerbations in the previous year (Sina Pharmaceutical News) Sanofi recently announced that the European Commission has approved insulin aspart Sanofi ® (insulin aspart, mendoinsulin, 100 units/ml) for use in children, adolescents and adults with type 1 and type 2 diabetes who are 1 year old and need insulin to control blood sugar levels, adolescents and adults, including those who have just been diagnosed with diabetes (Bio Valley) The First Three CoPharma recently announced that the European Medicines Agency has accepted the new breast cancer drug Enhertu marketing authorization application, the drug is a target HER2 antibody drug conjugate, for the treatment of at least 2 previously received anti-HER2 treatment regimen or metastatic HER2-positive breast cancer patients The EMA Human Products Committee has awarded Enhertu an accelerated assessment and has initiated a scientific review (Bio Valley) the U.S FDA announced that it has approved the listing of Inqovi tablets developed by Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceuticals, for the treatment of myelogenous abnormal syndrome and chronic granulocytic leukemia in adult patients Reding Pharmaceuticals and Turning Point Therapeutics have announced an exclusive licensing agreement to advance the development and commercialization of Turning Point's main candidate drug, Repotrectinib, in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan) Turning Point Therapeutics is a company dedicated to developing a new generation of cancer precision therapies for cancer-driven genes (Associated Press)